Results 11 to 20 of about 57 (53)

[When the risk exceeds the benefit]. [PDF]

Aten Primaria, 2004
Blasco Oliete M.
europepmc   +1 more source

[And spironolactone in the treatment of heart failure?]. [PDF]

Aten Primaria, 2000
Sastre García F, García Bernabé C, López Reinoso C, Arribas Mir L.   +3 more
europepmc   +1 more source

Miocarditis. [PDF]

Medicine (Baltimore), 2001
Pérez-Villa F.
europepmc   +1 more source

[Spironolactone in heart failure]. [PDF]

Aten Primaria, 2000
López Herrero F, Pardo Alvarez J.
europepmc   +1 more source

[Pharmaceutical marketing and intoxications due to emulation]. [PDF]

Aten Primaria, 2003
Burrillo-Putze G, Miró O, Nogué Xarau S.   +2 more
europepmc   +1 more source

[Randomised clinical trial to evaluate the efficacy of a multi-factorial intervention to reduce hospitalisation and improve the quality of life of patients with heart failure]. [PDF]

Aten Primaria, 2005
Brotons C, Martínez M, Rayó E, Morralla C, Ballarín E, Pérez E, Investigadores del Estudio IC-DOM.   +6 more
europepmc   +1 more source

[Restless legs syndrome: concerning two cases]. [PDF]

Aten Primaria, 2002
Caudevilla Gálligo F, Figueroa Martín-Buitrago M, Sánchez González R.   +2 more
europepmc   +1 more source

[Risk factors of a new cardio-embolic cerebral accident in non-valvular atrial fibrillation treated with acenocoumarol]. [PDF]

Aten Primaria, 2001
Vázquez Muñoz E, Gómez Cerezo J, Fernández Pavón A.   +2 more
europepmc   +1 more source

[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure]. [PDF]

Aten Primaria, 2000
Soto Alvarez J.
europepmc   +1 more source